What Are the Signs and Symptoms of ASMD?
ASMD types A/B and B: Manifestations progress less rapidly than in type A and may include any combination of the following1
Hepatomegaly is seen in>70% of patients1,2*
Symptoms of hepatomegaly include enlarged abdomen and abdominal pain1,3
LIVER
|
|
SPLEEN
|
|
LUNGS
|
|
HEMATOLOGIC
|
NEUROLOGIC
|
|
CARDIAC
|
|
SKELETAL
|
|
GROWTH AND DEVELOPMENT
|
*Symptom prevalence data for hepatomegaly is only for patients with ASMD type B.
References
- McGovern MM, et al. Orphanet J Rare Dis. 2017;12(1):41. doi:10.1186/s13023-017-0572-x
- Cox GF, et al. JIMD Rep. 2018;41:119-129.
- National Organization for Rare Disorders. Acid sphingomyelinase deficiency. Accessed February 3, 2023. https://rarediseases.org/rare-diseases/acid-sphingomyelinase-deficiency/?filter=Signs%2B%26%2BSymptomsa.
Potential Hepatic Manifestations of ASMD Often Overlap With Hepatic Disorders and Other Lysosomal Storage Diseases1
Potential hepatic symptoms of ASMD | ASMD1 | Chronic hepatitis B1-3 | Nonalcoholic fatty liver disease4,5 | Cryptogenic cirrhosis1,6,7 | Niemann-Pick disease type C1,8,9 | Lysosomal acid lipase deficiency1,10,11 | Gaucher disease1,12,13 |
Hepatomegaly | |||||||
Elevated hepatic enzymes | |||||||
Fibrosis/cirrhosis | |||||||
Hepatic failure | |||||||
Portal hypertension |
*Aminotransferase levels, such as AST and ALT, are typically only mildly elevated or normal in those with cryptogenic cirrhosis.6
†Development of end-stage liver disease is rare with Gaucher disease and tends to include the associated complications of hepatic decompensation.12
ALT=alanine aminotransferase; ASMD=acid sphingomyelinase deficiency; AST=aspartate aminotransferase.
References
- McGovern MM, et al. Genet Med. 2017;19(9):967-974.
- Hepatitis B Foundation. Other Tests. Accessed February 3, 2023. https://www.hepb.org/prevention-and-diagnosis/diagnosis/other-tests/#:~:text=If%20a%20person%20is%20infected,risk%20of%20potential% 20liver%20damage
- Terrault NA, et al. Hepatology. 2018;67(4):1560-1599.
- Chalasani N, et al. Hepatology. 2018;67(1):328-357.
- Miao L, et al. Port Hypertens Cirrhos. 2022;1:57-65.
- Patel N, et al. Cryptogenic cirrhosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 12, 2022.
- Mercado-Irizarry A, et al. Clin Liver Dis (Hoboken). 2016;7(4):69-72.
- Rodriguez-Gil JL, et al. Am J Med Genet A. 2021;185(10):3111-3117.
- Twarling A, et al. J Diagn Med Sonogr. 2004;20(4):198-201.
- Hoffman EP, et al. Lysosomal Acid Lipase Deficiency. In: Adam MP, et al, eds. GeneReviews®. University of Washington, Seattle; 2015. Initial posting July 30, 2015; last update September 1, 2016. Accessed January 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK305870/.
- Strebinger G, et al. Hepat Med. 2019;11:79-88.
- Adar T, et al. Blood Cells Mol Dis. 2018;68:66-73.
- Starosta RT, et al. Mol Genet Metab Rep. 2020;22:100564. doi:10.1016/j.ymgmr.2019.100564.